Post by Yelk on Apr 6, 2020 17:23:59 GMT
Hey guys,
Wanted to mention this one as its at the bottom right now and worth a look, tiny float. I won't be posting about every COVID company as there is too many but as it hasn't ramped up yet throw I'd through the idea out there.
CANF
Price $1.55
Catalysts:
- Started phase 2 COVID trial today (announced Friday, small bump) with 40 patients: clinicaltrials.gov/ct2/show/NCT04333472
- Readout of phase 2 data soon Namodenoson Phase II NASH Data Expected in April 2020 - Can-Fite completed enrollment of 60 patients with NAFLD (non-alcoholic fatty liver disease) with or without NASH (non-alcoholic steatohepatitis), and plans to announce topline results during April 2020
- Piclidenoson Phase III Rheumatoid Arthritis and Psoriasis Studies Complete 50% Enrollment; Interim Data for Rheumatoid Arthritis Expected Q4 2020
- Phase 3 data in Q4 and COVID trial started today with June-Aug action could open up buying opportunity even if bad April P2 news.
- Namodenoson is Headed into Pivotal Phase III Liver Cancer Study – Following a successful End-of-Phase II Meeting with the U.S. Food and Drug Administration (FDA) regarding
glad snagged some. Right delayed news Tuesday's. But it was only chump change as I wanted to average down on bad P2 news. Not sure how far this will go today, stronger markets, covid news, other catalysts and now this. Probably won't add cause too small a position but interested to see.